BackMaxCyte Overview

MaxCyte Cost of Revenue

Cost of Revenue analysis for MXCT.

Quarterly Cost of Revenue

$2.58M
72.68% YoY

As of Mar 31, 2026

Annual Cost of Revenue (TTM)

$12.62M
75.37% YoY

Trailing 12 months ending Mar 31, 2026

Average Cost of Revenue (Comparison Companies)

Cost of Revenue History

Cost of Revenue Comparison

Annual Cost of Revenue Growth Rate (%)

Annual Cost of Revenue Growth (Absolute)